Resources from the same session
1585MO - Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies
Presenter: Aida Bujosa Rodríguez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1586MO - Pivotal trial endpoints of drugs for rare and non-rare cancers in the US and Europe
Presenter: Kerstin Vokinger
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1587MO - How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature
Presenter: Karla Hernandez Villafuerte
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1588MO_PR - A comparative study on costs of cancer and access to medicines in Europe
Presenter: Nils Wilking
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1589MO - Opposition to a patent covering tisagenlecleucel: Using intellectual property (IP) legislation to defend sustainable access to cancer therapies
Presenter: Juliana Veras
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
1590MO - Income loss after a cancer diagnosis from the patient perspective: An analysis based upon the German Socio-Economic Panel (SOEP) survey
Presenter: Diego Hernandez
Session: Mini Oral - Public policy
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: William Evans
Session: Mini Oral - Public policy
Resources:
Webcast
Invited Discussant 1585MO and 1586MO_PR
Presenter: William Evans
Session: Mini Oral - Public policy
Resources:
Slides
Webcast
Invited Discussant 1589MO and 1590MO
Presenter: Tit Albreht
Session: Mini Oral - Public policy
Resources:
Slides
Webcast